PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Brownell, Anna Liisa ^a   Kuruppu, Darshini ^a   Kil, Kun Eek ^a   Jokivarsi, Kimmo ^a   Poutiainen, Pekka ^a   Zhu, Aijun ^a   Maxwell, Michelle ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ALS; Glutamate; Inflammation; MGluR5; 11C PBR28; 18F FPEB

Indexed keywords

3 FLUORO 5 (2 PYRIDYLETHYNYL)BENZONITRILE F 18; CARBON PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND 28 C 11; METABOTROPIC RECEPTOR 5; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GRM5 PROTEIN, MOUSE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; BRAIN REGION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; SOD1 GENE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, METABOTROPIC GLUTAMATE 5; SUPEROXIDE DISMUTASE;

EID: 84949099845     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0439-9     Document Type: Article

References (38)

1. Strong MJ. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacology and Therapeutics. 2003;98:379-414.
2. Corcia P, Gordon PH. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther Clin Risk Manag. 2012;8:359-66.
3. Dibaj P, Zschuntzsch J, Steffens H, Scheffel J, Goricke B, Weishaupt JH, et al. Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1(G93A) model for ALS. PLoS One. 2012;7(8), e43963.
4. Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci. 2013;53:34-41.
5. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601-9.
6. Giribaldi F, Milanese M, Bonifacio T, Anna Rossi PI, Di Prisco S, Pittaluga A, et al. Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 2013;66:253-63.
7. Kanki R, Nakamizo T, Yamashita H, Kihara T, Sawada H, Uemura K, et al. Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons. Brain Res. 2004;1015(1-2):73-81.
8. McDonnell M, Vera MD, Blass BE, Pelletier JC, King RC, Fernandez-Metzler C, et al. Riluzole prodrugs for melanoma and ALS: design, synthesis, and in vitro metabolic profiling. Bioorg Med Chem. 2012;20(18):5642-8.
9. Rahn KA, Slusher BS, Kaplin AI. Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem. 2012;19(9):1335-45.
10. Spalloni A, Nutini M, Longone P. Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2013;1832(2):312-22.
11. Yin HZ, Nalbandian A, Hsu CI, Li S, Llewellyn KJ, Mozaffar T, et al. Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis. 2012;3, e374. doi: 10.1038/cddis.2012.115.
12. Ghiasi P, Hosseinkhani S, Noori A, Nafissi S, Khajeh K. Mitochondrial complex I deficiency and ATP/ADP ratio in lymphocytes of amyotrophic lateral sclerosis patients. Neurol Res. 2012;34(3):297-303.
13. Shaw CE, al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2001;1(1):69-76.
14. Turner BJ, Atkin JD, Farg MA, da Zang W, Rembach A, Lopes EC, et al. Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J Neurosci. 2005;25(1):108-17.
15. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12(3):310-22.
16. Miller T, Cleveland DW. Treating neurodegenerative diseases with antibiotics. Science. 2005;307:361-2.
17. Rothstein J, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73-7.
18. Niswender C, Jones CK, Conn PJ. New therapeutic frontiers for metabotropic glutamate receptors. Curr Top Med Chem. 2005;5:847-57.
19. Pin P, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacol. 1995;34(1):1-26.
20. Annoura H, Fukunaga A, Uesugi M, Tatsuoka T, Horikawa Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropachromen-1a-carboxylates. Bioorg Med Chem Lett. 1996;6:763-6.
21. Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol. 2005;97(4):202-13.
22. Zhang Z, Brownell A-L. Imaging of metabotropic glutamate receptors. In: Bright P, Ruskin A, editors. Neuroimaging- Clinical Applications. Rijeka, Croatia: InTech-Open Access Publisher; 2012. p. 499-532
23. Williams JD, Lindsley CW. Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr Top Med Chem. 2005;5:825-46.
24. Aronica E, Catania MV, Geurts J, Yankaya B, Troost D. Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience. 2001;105(2):509-20.
25. O'Callaghan JP, Sriram K, Miller DB. Defining "neuroinflammation". Ann N Y Acad Sci. 2008;1139:318-30.
26. Appel S, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011;30(1):4-8.
27. Wang J, Tueckmantel W, Zhu A, Pellegrino D, Brownell A-L. Synthesis and preliminary biological evaluation of 3-[(18)F]fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse. 2007;61(12):951-61.
28. Yu M, Tueckmantel W, Wang X, Zhu A, Kozikowski AP, Brownell A-L. Methoxyphenylethynyl, methoxypyridylethynyl and phenylethynyl derivatives of pyridine: synthesis, radiolabeling and evaluation of new PET ligands for metabotropic glutamate subtype 5 receptors. Nucl Med Biol. 2005;32(6):631-40.
29. Zhu A, Wang X, Yu M, Wang JQ, Brownell A-L. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies. J Cereb Blood Flow Metab. 2007;27(9):1623-31.
30. Pellegrino D, Cicchetti F, Wang X, Zhu A, Yu M, Saint-Pierre M, et al. Modulation of brain dopaminergic and glutamatergic functions: microPET imaging studies in Parkinsonian rats. J Nucl Med. 2007;48(7):1147-53.
31. Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tueckmantel W, Kozikowski A, et al. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage. 2008;42(1):248-51.
32. Wang JQ, Brownell A-L. Development of metabotropic glutamate receptor ligands for neuroimaging. Curr Med Imag Rev. 2007;3:186-205.
33. Logan J, Wolf AP, Shiue CY, Fowler JS. Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers. J Neurochem. 1987;48:73-83.
34. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]- (-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-7.
35. Knippenberg S, Thau N, Dengler R, Petri S. Significance of behavioral tests in a transgenic mouse model of amyotrophic lateral sclerosis. Behav brain Res. 2010;213:82-7.
36. Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T, et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage. 2008;40(1):43-52.
37. Kreisl WC, Jenko KJ, HinesC S, Lyoo CH, Corona W, Morse CL, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33:53-8.
38. Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409-14.